As of Feb 21, 2025, Insmed Incorporated Intrinsic Value is $39.7. This suggests it may be overvalued by 51.1% compared to its current price of around $81.1.
As of Feb 21, 2025, Insmed Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $81.1, using a discount rate of 9.6% and terminal growth rate of 3.0%.
Insmed Incorporated is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $39.7, compared to a market price of around $81.1. This suggests a potential overvaluation of 51.1%.